Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making?

Soárez, Patrícia Coelho de; Novaes, Hillegonda Maria Dutilh; Sartori, Ana Marli Christovan

doi:10.1590/s0102-311x2009001500006

Cited by 15 publications

(6 citation statements)

References 54 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For instance, in a study on economic evaluation of varicella vaccination, the vaccine was not acceptable for a base-case analysis (not including the indirect cost). However, when the indirect cost was included, the vaccine is acceptable [ 35 ].…”

Section: Discussionmentioning

confidence: 99%

Cost of rotavirus diarrhea for programmatic evaluation of vaccination in Vietnam

Riewpaiboon

Shin

et al. 2016

BMC Public Health

View full text Add to dashboard Cite

BackgroundRotavirus is the most common etiology of diarrhea-associated hospitalizations and clinic visits in Vietnamese children < 5 years old. To estimate the economic burden of rotavirus-associated formal healthcare encounters, an economic study was conducted.MethodsA cost-of-illness study was performed from a societal perspective. Data were collected from children below the age of five years who presented to a clinic or hospital with symptoms of acute gastroenteritis (AGE). Patient-specific information on resource use and cost was obtained through caregiver interviews and medical chart review. Costs are presented in 2014 US dollar ($).ResultsA total of 557 children with symptoms of AGE were enrolled from March through June 2009, with mean age of 16.5 months. Of the 340 outpatients and 217 admitted patients enrolled, 41 % tested rotavirus positive. It was found that, from a societal perspective, the mean total cost of AGE was $175. Costs of patients with and without rotavirus were $217 and $158, respectively. From multiple regression analysis, it was found that rotavirus infection, patient age and receiving oral rehydration solution before visiting health facility had significant effect on the costs.ConclusionsThis study clearly demonstrated substantial economic burden of AGE including rotavirus disease. They were significantly greater than the previously reported cost estimates in Vietnam. These updated costs of illness result in more favorable vaccine cost-effectiveness than in previous economic evaluations.

show abstract

Section: Discussionmentioning

confidence: 99%

Cost of rotavirus diarrhea for programmatic evaluation of vaccination in Vietnam

Riewpaiboon

Shin

et al. 2016

BMC Public Health

View full text Add to dashboard Cite

show abstract

“…The cost-effectiveness of varicella vaccination has been analyzed in several studies. [14][15][16][17][18] The results suggest that dynamic transmission models are more accurate than static models at capturing the indirect effects of varicella vaccination (e.g., herd immunity, age distribution of varicella cases, incidence of herpes zoster), 14,16,17 and, thus, dynamic transmission models have become the gold standard. However, publications on budget-impact models in low-and middleincome countries are sparse, despite their importance for decision making.…”

Section: Introductionmentioning

confidence: 99%

Budget impact analysis of multiple varicella vaccination strategies: a Mexico perspective

Graham

Wolfson

Kyle

et al. 2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

A number of live-attenuated varicella vaccines are produced globally that provide protection against the varicella zoster virus. In Mexico, varicella vaccination is not included in the national immunization program and is recommended for use only in high-risk subgroups. We developed a budget impact model to estimate the impact of universal childhood immunization against varicella on the national payer system in Mexico. A scenario of no varicella vaccination was compared to scenarios with vaccination with a single dose at 13 months of age, in alignment with the existing program of immunization with the measles-mumps-rubella vaccine. Nine different vaccination scenarios were envisioned, differing by vaccine type and by coverage. Varicella cases and treatment costs of each scenario were computed in a dynamic transmission model of varicella epidemiology, calibrated to the population of Mexico. Unit costs were based on Mexico sources or were from the literature. The results indicated that each of the three vaccine types increased vaccine acquisition and administration expenditures but produced overall cost savings in each of the first 10 years of the program, due to fewer cases and reduced varicella treatment costs. A highly effective vaccine at 95% coverage produced the greatest cost savings.

show abstract

“…Indeed, Zhou and colleagues have shown that the two-dose regimen is cost-effective when compared with no vaccination but not when compared with the one-dose regimen [Zhou et al 2008]. Moreover, it is important to understand that there is a considerable heterogeneity in the methodologies used in different studies which have an impact on their results [Soarez et al 2009]. More specifically, the type of model used (static versus dynamic), the perspective examined (whether society's perspective is added to that of providers), the inclusion of the herd immunity effect and vaccination coverage and the different amounts used for vaccine price and parental wages also had a significant impact on the computed results.…”

Section: Cost-effectiveness Studies Evaluating the Introduction Of Vamentioning

confidence: 99%

Successes and challenges in varicella vaccine

Papaloukas

Giannouli

Papaevangelou

2014

Therapeutic Advances in Vaccines

View full text Add to dashboard Cite

Varicella is a highly contagious disease caused by primary infection with varicella zoster virus (VZV). VZV infection, as well as varicella vaccination, induces VZV-specific antibody and T-cell-mediated immunity, essential for recovery. The immune responses developed contribute to protection following re-exposure to VZV. When cell-mediated immunity declines, as occurs with aging or immunosuppression, reactivation of VZV leads to herpes zoster (HZ). It has been almost 20 years since universal varicella vaccination has been implemented in many areas around the globe and this has resulted in a significant reduction of varicella-associated disease burden. Successes are reviewed here, whilst emphasis is put on the challenges ahead. Most countries that have not implemented routine childhood varicella vaccination have chosen to vaccinate high-risk groups alone. The main reasons for not introducing universal vaccination are discussed, including fear of age shift of peak incidence age and of HZ incidence increase. Possible reasons for not observing the predicted increase in HZ incidence are explored. The advantages and disadvantages of universal vs targeted vaccination as well as different vaccination schedules are discussed.

show abstract

Impact of methodology on the results of economic evaluations of varicella vaccination programs: is it important for decision-making?

Abstract: Abstract

Cited by 15 publications

References 54 publications

Cost of rotavirus diarrhea for programmatic evaluation of vaccination in Vietnam

Cost of rotavirus diarrhea for programmatic evaluation of vaccination in Vietnam

Budget impact analysis of multiple varicella vaccination strategies: a Mexico perspective

Successes and challenges in varicella vaccine

Contact Info

Product

Resources

About